Dr. Rhie received her B.S. in Biochemistry, magna cum laude from the University of California, Los Angeles. She earned her Ph.D. degree in Genetic, Molecular and Cellular Biology from the University of Southern California in 2013. She completed her postdoctoral training in the laboratories of Dr. Peter Laird and Dr. Peggy Farnham. Dr. Rhie participated in Genome-Wide Association Studies (GWAS) in different cancer types, unraveling mechanisms that explain how genetic variants affect disease risks. Dr. Rhie characterized heterogeneous tumor tissues as a leader of DNA methylation analysis for The Cancer Genome Atlas (TCGA) Consortium and discovered how genetic alterations such as somatic mutations, fusions, copy number variations are associated with epigenetic changes in cancer. She has also led epigenomic data analysis to investigate how transcription factors act at regulatory elements in a 3D nucleome structure in cancer and psychiatric diseases as part of the ENCODE and PsychENCODE Consortia.
Her current research interests are to characterize key transcription factor and understand roles of regulatory elements activated in different types of cancers and neurodevelopmental diseases. By using both molecular biology and bioinformatics to address how genes are regulated in 3D nucleome structure (e.g. ChIP-seq, RNA-seq, whole genome sequencing, whole genome bisulfite sequencing, NOMe-seq, DNA methylation, Hi-C, CRISPR/Cas9, dCas9-ED systems), her lab is discovering new molecular mechanisms of human diseases that can aid in the development of therapeutics to enhance quality of life for patients.